News UCB SA OTC Markets

Equities

UCBJY

US9034801012

Market Closed - OTC Markets Other stock markets 13:58:03 2024-06-07 EDT			5-day change	1st Jan Change
70.25 ^USD	-0.77%		+0.82%	+61.12%

04-11	Berenberg Reiterates UCB's Purchase Rating, Raises PT	MT
04-11	UCB : Berenberg, Buy, raises its price target	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UCB : Acquisition of own shares	05-31	PU
UCB : Commitment to Innovation in Drug Development	05-29	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	05-23	PU
UCB - Acquisition of own shares	05-20	AQ
UCB : Transparency notification Wellington	05-17	PU
UCB : Acquisition of own shares	05-17	PU
UCB - Acquisition of own shares	05-13	AQ
UCB : Acquisition of own shares	05-10	PU
UCB presents final open-label extension F data at International Child Neurology Congress Annual Meeting	05-09	AQ
UCB : presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	05-08	PU
UCB : presents final open-label extension FINTEPLA®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting	05-07	PU
UCB - Acquisition of own shares	05-06	AQ
UCB : Acquisition of own shares	04-26	PU
Pioneering innovation, fueling growth: UCB's commitment to delivering differentiated solutions	04-26	PU
Ex-dividend day for final dividend	04-25	FA
UCB : General Meeting of Shareholders 2024	04-25	PU
UCB : receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa	04-22	PU
UCB : FINTEPLA▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)	04-17	PU
UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology Annual Meeting	04-15	AQ
UCB : Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY▼ (romosozumab) can help to close the treatment gap in osteoporosi	04-12	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

UCB : UCB all set to reach new highs

March 08, 2024 at 11:10 am